Osteomyelitis — infection of bone — is one of the most challenging complications that can arise in a diabetic foot wound. It occurs in an estimated 10–15% of all diabetic foot infections and in up to 66% of severe infections, and it significantly increases the risk of amputation when not recognized and managed promptly. Understanding how osteomyelitis develops, how it is diagnosed, and what the current evidence says about treatment is essential for clinicians and informed patients alike.
How Bone Infection Develops in the Diabetic Foot
In patients with diabetes, the pathway to osteomyelitis typically begins with peripheral neuropathy and vascular disease impairing wound healing. An ulcer on the plantar surface or toe fails to close, allowing bacteria to invade the underlying soft tissue and, over time, the adjacent bone. The most commonly affected sites are the forefoot — particularly the metatarsal heads and toe phalanges — because these areas bear repetitive mechanical pressure from walking.
Staphylococcus aureus remains the most frequently isolated pathogen, though polymicrobial infections with gram-negative and anaerobic organisms are common in more severe or long-standing wounds. Once bacterial biofilm establishes in bone, standard antibiotic penetration and immune clearance become substantially less effective, making early detection critical.
Diagnosing Diabetic Foot Osteomyelitis
Diagnosis relies on a combination of clinical examination, laboratory markers, imaging, and, in definitive cases, bone biopsy. The 2023 joint guidelines from the International Working Group on the Diabetic Foot (IWGDF) and the Infectious Diseases Society of America (IDSA) provide the most current evidence-based framework for this process.
The probe-to-bone (PTB) test — inserting a sterile metal probe through an ulcer to determine whether bone can be contacted — is a rapid bedside screening tool. A systematic review published in Clinical Infectious Diseases (Lam et al., 2016) pooled data from seven studies and reported a sensitivity of 0.87 and specificity of 0.83 for the PTB test, with a negative predictive value approaching 0.98 in low-to-moderate prevalence settings. A negative PTB test substantially reduces the probability of osteomyelitis.
Plain radiography is typically the first imaging step and may reveal cortical erosion, periosteal reaction, or bone destruction, but these changes often lag weeks behind actual infection. MRI is the preferred advanced imaging modality, with sensitivity around 90% and specificity of approximately 79% — substantially better than X-ray alone. MRI can delineate the extent of bone marrow involvement and guide surgical planning.
Bone biopsy with culture and histopathology remains the diagnostic gold standard, with reported sensitivity of approximately 95% and specificity of 99%. Biopsy identifies the causative organisms and their antibiotic susceptibility profiles, allowing targeted therapy. The 2023 IWGDF/IDSA guidelines recommend microbiological cultures from bone whenever clinically feasible and advise using conventional (not molecular) techniques for pathogen identification.
Antibiotic Treatment: Duration and Route
Antibiotic therapy is a cornerstone of osteomyelitis management, whether used as the primary treatment strategy or as an adjunct to surgery. The 2023 IWGDF/IDSA guidelines recommend approximately six weeks of antibiotic therapy when no surgical bone resection is performed, and approximately three weeks following minor amputation or limited bone resection with clear margins.
Historically, prolonged intravenous therapy was considered standard, but growing evidence supports the equivalence of oral antibiotics with high bioavailability. The landmark OVIVA trial demonstrated that oral antibiotic therapy was non-inferior to intravenous therapy for bone and joint infections, and a 2025 systematic review and meta-analysis specifically examining diabetic foot osteomyelitis (published in Clinical Microbiology and Infection Communications) found no statistically significant difference in treatment success between IV and oral treatment groups. Oral therapy offers practical advantages including reduced line-related complications, earlier hospital discharge, and lower cost.
A Cochrane-reviewed systematic review on antibiotic duration (published in Antibiotics, 2024) found that shorter courses (under 6 weeks) showed comparable major amputation rates (~10%) to longer courses, though remission data showed variability across studies. Current guidance continues to favour the six-week threshold as a reasonable standard for non-operative management.
Surgery: Conservative Approaches and Limb Salvage
When osteomyelitis is associated with necrotic tissue, exposed bone, or failure of medical therapy, surgery is generally required. The 2023 IWGDF/IDSA guidelines emphasize early surgical intervention — within 24–48 hours — for moderate-to-severe infections, recommending a conservative approach that removes infected and necrotic bone while preserving as much functional foot architecture as possible.
A 2022 meta-analysis published in Open Forum Infectious Diseases (Wukich et al.) compared outcomes across studies: surgical-medical combined treatment achieved an average success rate of 85.7%, compared to 68.2% for medical management alone. These figures underscore the importance of timely surgical consultation in appropriate cases.
Residual osteomyelitis after surgery carries significant consequences. A 2024 systematic review and meta-analysis in Wound Repair and Regeneration (Reyes et al.) found that patients with residual osteomyelitis following surgical treatment had a 2.0-fold higher risk of recurrent infection and a 4.3-fold higher risk of amputation. These findings reinforce the value of achieving clear surgical margins confirmed by intraoperative bone culture and histopathology.
Key Clinical Takeaways
Diabetic foot osteomyelitis demands early recognition through a structured diagnostic approach: clinical assessment, probe-to-bone testing, plain radiography, and MRI when indicated. Bone biopsy provides definitive diagnosis and guides targeted antibiotic selection. The current evidence supports six weeks of antibiotic therapy — with oral regimens increasingly recognized as effective alternatives to intravenous routes. When surgery is needed, conservative foot-sparing resection, guided by multidisciplinary teams and confirmed clear margins, offers the best chance of remission and limb salvage.
References
- Lipsky BA, Senneville É, Abbas ZG, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad527
- Lam K, van Asten SAV, Nguyen T, La Fontaine J, Lavery LA. Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review. Clinical Infectious Diseases. 2016;63(7):944–948.
- Wukich DK, Hobizal KB, Sambenedetto TL, et al. Meta-Analysis: Outcomes of Surgical and Medical Management of Diabetic Foot Osteomyelitis. Open Forum Infectious Diseases. 2022;9(9):ofac407.
- Tone A, Nguyen S, Lavigne F, et al. Six-Week Versus Twelve-Week Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis. Diabetes Care. 2015;38(2):302–307.
- Reyes R, López D, Hernández A, et al. Residual diabetic foot osteomyelitis after surgery leads to poor clinical outcomes: A systematic review and meta-analysis. Wound Repair and Regeneration. 2024. doi:10.1111/wrr.13215
- Rodríguez-Sánchez B, Martínez-González J, Blanco A, et al. Impact of antibiotic duration in management of diabetic foot osteomyelitis: A systematic review and meta-analysis. Clinical Microbiology and Infection Communications. 2025.
Comments
